News | October 18, 2010

Italian Man Surpasses 1,000 Days Of Support With Artificial Heart

October 18, 2010 - A 54-year-old Italian man has become the first patient to surpass 1,000 days of support with an artificial heart while waiting for a matching donor heart. The patient was implanted with the SynCardia temporary Total Artificial Heart.

“Life is a wonderful present that has to be respected,” said patient Pietro Zorzetto. “The Total Artificial Heart allowed me to recover to a very healthy physical condition. I really want to thank the SynCardia Total Artificial Heart for these unexpected 1,000 days of life.”

Zorzetto was first admitted to Azienda Ospedaliera di Padova on Nov. 30, 2007, suffering from valvular cardiomyopathy. Two previous operations at a different hospital had failed to repair his failing heart. Less than a week later, Zorzetto made history when he became the first patient in Italy to be implanted with the SynCardia Total Artificial Heart.

“The Total Artificial Heart provides excellent cardiac output, which restored our patient to normal condition despite the fact he presented with severe multi-organ failure,” said professor Gino Gerosa. “The Total Artificial Heart in combination with the portable driver has been extremely effective in providing the patient with a good quality of life with excellent exercise capacity.”

Zorzetto has been at home since Feb. 4, 2008, when he was discharged from the hospital using a portable driver to power his artificial heart. On a typical day, he walks 10 km and then exercises for an additional 30 minutes in his gym at home to stay in shape for a transplant.

For more information: www.syncardia.com

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init